US EditionWave Life Sciences: Update on 48-week Data from FORWARD-53 Exon Skipping Study
Summary by CureDuchenne
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Wave Life Sciences: Update on 48-week Data from FORWARD-53 Exon Skipping Study
Wave Life Science Exon Skipping in DuchenneWave Life Sciences: Update on 48-week Data from FORWARD-53 Exon Skipping Study: An update on Wave’s Phase 2 FORWARD-53 trial of WE-N531, Wave’s exon skipping investigational therapy for Duchenne being investigated for individuals who are amenable to exon 53 skipping. We will share the recently announced 48-week FORWARD-53 data.Watch the webinar HEREThe post Wave Life Sciences: Update on 48-week Data fro…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage